GKL-006
/ Beijing Gene Key Life Technology
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
October 08, 2025
GKL-006 Combined With TACE in Treatment of Unresectable Hepatocellular Carcinoma
(clinicaltrials.gov)
- P2 | N=48 | Not yet recruiting | Sponsor: Beijing Gene Key Life Technology Co., Ltd
New P2 trial • Hepatocellular Cancer • Oncology • Solid Tumor
January 16, 2024
Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy
(clinicaltrials.gov)
- P2 | N=84 | Recruiting | Sponsor: Beijing YouAn Hospital | Not yet recruiting ➔ Recruiting
Enrollment open • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor
1 to 2
Of
2
Go to page
1